1.World Health OrganizationAssessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. Geneva: World Health Organization; 1994.
2.Choi YJ, Oh HJ, Kim DJ, Lee Y, Chung YS. The preva-lence of osteoporosis in Korean adults aged 50 years or older and the higher diagnosis rates in women who were beneficiaries of a national screening program: the Korea National Health and Nutrition Examination Survey 2008-2009. J Bone Miner Res 2012;27:1879-86.
4.Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007;166:495-505.
6.Krakauer JC, McKenna MJ, Buderer NF, Rao DS, White-house FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995;44:775-82.
7.Liu Z, Aronson J, Wahl EC, Liu L, Perrien DS, Kern PA, et al. A novel rat model for the study of deficits in bone for-mation in type-2 diabetes. Acta Orthop 2007;78:46-55.
9.Kurra S, Fink DA, Siris ES. Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin North Am 2014;43:233-43.
11.Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 2014;68:115-23.
15.Adil M, Khan RA, Kalam A, Venkata SK, Kandhare AD, Ghosh P, et al. Effect of anti-diabetic drugs on bone me-tabolism: evidence from preclinical and clinical studies. Pharmacol Rep 2017;69:1328-40.
18.Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D, Goulis DG. Type 2 diabetes and osteoporosis: a guide to optimal management. J Clin Endocrinol Metab 2017;102:3621-34.
22.Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002;25:1749-54.
24.Clowes JA, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 2005;20:1497-506.
28.Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and re-nal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
31.van Dalem J, Werkman NCC, van den Bergh JP, Rossi B, Viggers R, Eastell R, et al. Use of sodium-glucose co-trans-porter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort study. Diabetes Res Clin Pract 2022;190:109993.